|
|
|
|
Update on smoking cessation
It is no surprise that the Surgeon General's latest report states that smoking affects every organ system. The tobacco cessation guideline from the USPHS that recommends nicotine replacement therapy or bupropion for nearly all patients who smoke remains an effective strategy.
|
| |
More>>
|
|
|
|
|
|
Long-awaited drug fights renal cancer
For the first time in more than 10 years, the Food & Drug Administration has granted marketing approval to a drug for kidney cancer. Sorafenib was recently approved for the treatment of advanced renal cell carcinoma, the most common form of the disease. Sorafenib is currently available through specialty pharmacies.
|
| |
More>>
|
|
|
|
|
|
Optimizing management of HF
A 60-year-old African-American male, G.H., is admitted to your hospital with shortness of breath, peripheral edema, and 10-lb. weight gain, diagnosed as New York Heart Association Class III heart failure (HF).
|
| |
More>>
|
|
|
|
|
|
Muraglitazar: A dual peroxisome proliferator-activated receptor agonist
Muraglitazar is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. Available clinical data describe improvements in glycemic parameters similar to available thiazolidinediones. Safety data are limited, but in available abstracts, there are reports of moderately elevated rates of edema, weight gain, and hypoglycemia with muraglitazar compared with placebo or pioglitazone.
|
| |
More>>
|
|
|